Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/43065
Title: Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy
Authors: Henríquez-Hernández, Luis Alberto 
Murias-Rosales, Adolfo
González-Hernández, Ana
de León, Antonio Cabrera
Díaz-Chico, Nicolás 
Fernández-Pérez, Leandro 
Keywords: Acute Lymphoblastic-Leukemia
Methylenetetrahydrofolate Reductase C677T
Colorectal-Cancer
Thymidylate Synthase
Clinical-Practice, et al
Issue Date: 2010
Publisher: 1877-7821
Journal: Cancer Epidemiology 
Abstract: Purpose To investigate the role of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms in breast cancer patients treated with 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy. Results Observed allelic frequencies were: TSER, (2) 0.54 and (3) 0.46; MTHFR C677T, (C) 0.59 and (T) 0.41; p53 Arg72Pro, (Arg) 0.73 and (Pro) 0.27; MDR1 C3435T, (C) 0.52 and (T) 0.48. MTHFR allele T and p53 allele Pro were strongly associated with toxicity due to chemotherapy (odds ratio, 7.1 (95% confidence interval, 1.4-36.1; p = 0.018) and 7.0 (95% confidence interval, 1.2-40.5; p = 0.029), respectively). Conclusion We introduced new data related to the contribution of p53 codon 72 to toxicity due to 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy in patients with breast cancer. (C) 2010 Elsevier Ltd. All rights reserved.
URI: http://hdl.handle.net/10553/43065
ISSN: 1877-7821
DOI: 10.1016/j.canep.2010.06.013
Source: Cancer Epidemiology[ISSN 1877-7821],v. 34, p. 634-638
Appears in Collections:Artículos
Show full item record

SCOPUSTM   
Citations

29
checked on Mar 30, 2025

WEB OF SCIENCETM
Citations

27
checked on Mar 30, 2025

Page view(s)

104
checked on Jan 11, 2025

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.